Additional file 9: of The neoepitope landscape of breast cancer: implications for immunotherapy

Figure S7. Expression analysis for the high affinity neoepitopes (FPKM ≥2). (A) The number of the expressed neoepitopes (normalized by total number of samples in each breast cancer subtype) is shown for each FPKM range. 51% (8927/17518) of predicted neoepitopes are expressed with an FPKM threshold of ≥2. (B) Number of neoepitopes (normalized by the number of samples in each breast cancer subtype) with the highest expressed neoepitope for each patient as shown. 93% (762/815) of patients have at least one potential binding epitope.